Search BCRX
BIOCRYST PHARMACEUTICALS INC
Nasdaq · CIK 882796
Last close8.17
Daily change+0.05 (0.62%)
10 Years gain+78.38%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BCRX · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
29.0Momentum
n/aAcceleration
n/aConfidence
62.0Annual Revenue9
Quarterly Revenue35
Annual CFO16
Balance SheetMissing
RankingLimited
Score Breakdown
Growth11.9 / 25
Quality15.6 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Key Metrics
Revenue Growth TTM-4.43%OK
Revenue CAGR 3Y22.78%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $855.76M | $340.99M | $347.37M | $344.90M | n/a | n/a | n/a | n/a | 218.58M |
| 2025 FY Dec 31, 2024 | n/a | $438.44M | -$2.54M | -$52.02M | -$53.14M | n/a | n/a | n/a | n/a | 206.7M |
| 2025 FY Dec 31, 2023 | n/a | $326.93M | -$103.71M | -$95.14M | -$97.31M | n/a | n/a | n/a | n/a | 192.2M |
| 2024 FY Dec 31, 2022 | n/a | $264.23M | -$148.44M | -$161.85M | -$163.20M | n/a | n/a | n/a | n/a | 185.91M |
| 2023 FY Dec 31, 2021 | n/a | $149.91M | -$177.72M | -$142.16M | -$144.54M | n/a | n/a | n/a | n/a | 179.12M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $25.19M | sum latest 4 fiscal quarters Revenue | OK | 0001171843-17-002784, 0001171843-17-004830 |
| Revenue Growth TTM | -4.43% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001171843-17-002784, 0001171843-17-004830 |
| Revenue CAGR 3Y | 22.78% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001171843-18-001855 |
| Revenue CAGR 5Y | -0.86% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001171843-18-001855 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | derived |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | derived |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |
| Gross Margin Delta 3Y | n/a | GrossMargin_current - GrossMargin_3Y_ago | INSUFFICIENT_HISTORY | derived |
| Operating Margin Delta 1Y | n/a | OperatingMargin_current - OperatingMargin_prior_year | INSUFFICIENT_HISTORY | derived |